Insider Trading March 24, 2026

BCP Investment Compliance Chief Adds $6,894 Stake as Shares Hover Near 52-Week Low

David Held reports purchase of 938 shares; company posts Q4 2025 beats even as NAV and net investment income show weakness

By Ajmal Hussain BCIC
BCP Investment Compliance Chief Adds $6,894 Stake as Shares Hover Near 52-Week Low
BCIC

David Held, Chief Compliance Officer at BCP Investment Corp (NASDAQ: BCIC), purchased 938 shares on March 23, 2026, totaling $6,894. The transaction leaves Held with 1,258 shares. The stock is trading close to its 52-week low, and the firm reported quarterly results that beat consensus on EPS and revenue while other metrics, including net asset value and net investment income, showed deterioration prompting a price-target cut from Keefe, Bruyette & Woods.

Key Points

  • BCP Investment Chief Compliance Officer David Held bought 938 shares at $7.35 on March 23, 2026, totaling $6,894.
  • After the purchase Held holds 1,258 shares; BCIC was trading at $7.45 and near its 52-week low of $7.15, down 10% over the prior week.
  • BCP Investment beat Q4 2025 EPS ($0.57 vs $0.5325) and revenue ($17.5M vs $16.98M) while KBW cut its price target to $9.00, citing weaker net investment income and a 5% NAV decline.

David Held, the Chief Compliance Officer of BCP Investment Corp (NASDAQ: BCIC), disclosed a purchase of 938 shares of the companys common stock on March 23, 2026, in a Form 4 filing with the Securities and Exchange Commission. The shares were acquired at $7.35 apiece, producing a total outlay of $6,894.

Following the reported buy, Held directly holds 1,258 shares of BCP Investment Corp. The transaction occurred as the shares traded in the vicinity of their 52-week low of $7.15; the stock is currently quoted at $7.45 after a one-week decline of 10%.

Data cited from InvestingPro notes that BCIC carries a dividend yield of 22% and is among more than 1,400 U.S. equities covered by InvestingPros Pro Research Reports.


Quarterly performance highlights

BCP Investment reported fourth-quarter 2025 results that exceeded analyst expectations on both earnings and revenue. The company recorded earnings per share of $0.57, outpacing the forecast of $0.5325 by 7.04%. Revenue for the quarter reached $17.5 million versus an expected $16.98 million.

Despite the top-line and EPS beats, Keefe, Bruyette & Woods reduced its price target on BCP Investment from $14.00 to $9.00 while maintaining a Market Perform rating. The firm called attention to a challenging quarter, pointing to net investment income that fell short of expectations and a net asset value that declined by 5% in the period. BCP Investment reported an operating return on equity of 7% for the quarter.

These developments present a mixed picture: earnings and revenue exceeded consensus, yet other key metrics reflected operational pressure.


Context for investors

  • Insider purchase: A Form 4 filing records a small-scale acquisition by a senior officer, adding 938 shares at $7.35 on March 23, 2026.
  • Share position: After the purchase, Held owns 1,258 shares directly.
  • Company results: Q4 2025 EPS and revenue topped analyst estimates; NAV fell 5% and net investment income missed expectations, per Keefe, Bruyette & Woods.

Readers should note that the facts above are drawn from the companys regulatory filing, third-party data points, and the research house commentary disclosed in company reporting.

Risks

  • Net investment income underperformance and a 5% decline in net asset value highlight earnings quality and valuation risks for investors in BCP Investment - impacting the financials and investment management sectors.
  • Share-price volatility is evident with a 10% one-week decline and proximity to the 52-week low, signaling market sensitivity in the closed-end fund and broader markets sector.
  • Analyst revisions, such as KBWs price-target reduction from $14.00 to $9.00 while keeping a Market Perform rating, introduce uncertainty around near-term valuation expectations - affecting investor sentiment in financial equities.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026